Bristol Taxol Exclusivity Continues, Thanks To ABI Cremophor-Free Patent

Bristol-Myers Squibb's latest extension to the exclusivity for Taxol depends on continued rulings against the company in patent litigation in the Los Angeles federal court.

More from Archive

More from Pink Sheet